Newamsterdam Pharma Company Nv (NAMS)

Mar 10, 2025

A better buy-in window may exist right now for NewAmsterdam Pharma Company NV (NAMS) - SETE News

Mar 10, 2025

Mar 06, 2025

Newamsterdam pharma director James Topper buys $84,203 in shares By Investing.com - Investing.com South Africa

Mar 06, 2025

Mar 06, 2025

Newamsterdam pharma director James Topper buys $84,203 in shares - Investing.com

Mar 06, 2025

Mar 05, 2025

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares - Investing.com Australia

Mar 05, 2025

Mar 05, 2025

New Amsterdam Pharma chief accounting officer sells $3.06 million in shares By Investing.com - Investing.com South Africa

Mar 05, 2025

Mar 03, 2025

William Blair Has Negative Forecast for NAMS Q1 Earnings - Defense World

Mar 03, 2025

Mar 02, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Price Target Raised to $52.00 - Defense World

Mar 02, 2025

Mar 01, 2025

(NAMS) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 01, 2025

Feb 28, 2025

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib - Seeking Alpha

Feb 28, 2025

Feb 28, 2025

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution (NASDAQ:NAMS) - Seeking Alpha

Feb 28, 2025

Feb 28, 2025

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Feb 28, 2025

Feb 28, 2025

NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress - TipRanks

Feb 28, 2025

Feb 27, 2025

7 Analysts Have This To Say About NewAmsterdam Pharma - Benzinga

Feb 27, 2025

Feb 27, 2025

Scotiabank raises NewAmsterdam Pharma target to $52 - Investing.com India

Feb 27, 2025

Feb 27, 2025

Scotiabank raises NewAmsterdam Pharma target to $52 By Investing.com - Investing.com South Africa

Feb 27, 2025

Feb 27, 2025

Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence - TipRanks

Feb 27, 2025

Feb 26, 2025

NewAmsterdam Pharma's Full-Year Net Loss Widens, Revenue Rises -February 26, 2025 at 08:27 am EST - Marketscreener.com

Feb 26, 2025

Feb 26, 2025

Earnings Flash (NAMS) NewAmsterdam Pharma Posts Full Year 2024 Revenue $45.6M, vs. FactSet Est of $33.8M - Marketscreener.com

Feb 26, 2025

Feb 26, 2025

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Feb 26, 2025

Feb 26, 2025

NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView

Feb 26, 2025

Feb 26, 2025

Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction - StockTitan

Feb 26, 2025

Feb 25, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - The Manila Times

Feb 25, 2025

Feb 24, 2025

NewAmsterdam Pharma Company N.V. (NAMS): Among the Oversold Biotech Stocks to Buy Now - Insider Monkey

Feb 24, 2025

Feb 24, 2025

10 Oversold Biotech Stocks to Buy Now - Insider Monkey

Feb 24, 2025

Feb 24, 2025

How to Take Advantage of moves in (NAMSW) - Stock Traders Daily

Feb 24, 2025

Feb 21, 2025

Newamsterdam pharma COO sells shares worth $1.8 million - Investing.com India

Feb 21, 2025

Feb 20, 2025

Newamsterdam pharma COO sells shares worth $1.8 million By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 18, 2025

How To Trade (NAMS) - Stock Traders Daily

Feb 18, 2025

Feb 15, 2025

Mirae Asset Global Investments Co. Ltd. Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - Defense World

Feb 15, 2025

Feb 14, 2025

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease - Yahoo Finance

Feb 14, 2025

Feb 14, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Feb 14, 2025

Feb 13, 2025

abrdn plc Raises Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Feb 13, 2025

Feb 12, 2025

Newamsterdam pharma CFO sells shares worth $1.5 million - MSN

Feb 12, 2025

Feb 07, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 07, 2025

Feb 07, 2025

Where are the Opportunities in (NAMS) - Stock Traders Daily

Feb 07, 2025

Feb 07, 2025

Make Informed Decisions with NewAmsterdam Pharma Company NV (NAMS) Stock Updates - The News Heater

Feb 07, 2025

Feb 07, 2025

Ratios Uncovered: Breaking Down NewAmsterdam Pharma Company NV (NAMS)’s Trailing Twelve Months Metrics - The Dwinnex

Feb 07, 2025

Feb 07, 2025

NAMS: Strategic Executive Compensation Plan Unveiled138K Shares at $21.36 - StockTitan

Feb 07, 2025

Feb 06, 2025

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday? - AOL

Feb 06, 2025

Feb 06, 2025

Results from NewAmsterdam Pharma Company NV (NAMS) show risk - US Post News

Feb 06, 2025

Feb 06, 2025

China Universal Asset Management Co. Ltd. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Feb 06, 2025

Feb 05, 2025

H.C. Wainwright initates NewAmsterdam Pharma Company NV (NAMS) rating to a Buy - Knox Daily

Feb 05, 2025

Feb 04, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1%Still a Buy? - MarketBeat

Feb 04, 2025

Feb 03, 2025

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

Feb 03, 2025

Feb 02, 2025

JPMorgan Chase & Co. Increases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Feb 02, 2025

Feb 02, 2025

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Moody Aldrich Partners LLC - MarketBeat

Feb 02, 2025

Feb 01, 2025

How To Trade (NAMSW) - Stock Traders Daily

Feb 01, 2025